Try this search over all volumes: GlaxoSmithKline
Results 1-0 of 0
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
AstraZeneca Background BEACOPP Bristol-Myers Squibb Cancer Center Hospital Canfosfamide carboplatin chemotherapy cisplatin Clinical Oncology Conclusions cycles disclosure disease docetaxel dose doxorubicin drugs ECOG efficacy EGFR Eli Lilly eligible EORTC gefitinib gemcitabine Germany GlaxoSmithKline grade hazard ratio HBV reactivation HighD Hoffman-La Roche immediate family member—defined involving the sharing Japan Journal of Clinical larynx lenalidomide logrank test LowD ltaly lung cancer matter under consideration median age Median PFS median survival member—defined as someone metastatic months non-inferiority NSCLC Oncology ovarian cancer overall survival patients pts Pemetrexed peri-operative phase lll study phase lll trial PM Phase primary endpoint pts received randomized phase lll rash relationship involving resistant OC respectively response rate Results Roche sanofi-aventis secondary endpoints sharing of income Society of Clinical Sorafenib statistically significant Subgroup Telik tetracycline therapy toxicity treatment United Kingdom University Hospital versus vinorelbine